XML 80 R71.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaborations and Other Arrangements (Details) $ in Thousands, € in Millions |  |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Mar. 23, 2021 USD ($) | Feb. 01, 2021 USD ($) item | Nov. 04, 2019 | Mar. 31, 2024 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Oct. 31, 2018 USD ($) item | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 EUR (€) | Oct. 27, 2023 USD ($) | May 02, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, amount |  |  |  | $ 12,500 |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | $ 91,833 | $ 96,110 |  |  |
Royalties due |  |  |  |  |  |  |  |  | 38,400 |  |  |
Vaccinex License Agreement |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments to be made | $ 3,500 |  |  |  |  |  |  |  |  |  |  |
Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products | $ 11,500 |  |  |  |  |  |  |  |  |  |  |
Bioeq IP AG |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Percentage of gross profits shared |  |  | 50.00% |  |  |  |  |  |  |  |  |
Bioeq IP AG | Licensed Products |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payments related to FDA approval | € |  |  |  |  |  |  |  |  |  | € 2.5 |  |
Adimab Development and Option Agreement |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Minimum antibodies to be commercialized under commercialization option | item |  |  |  |  |  |  | 1 |  |  |  |  |
Period for payment of nominal research maintenance fee |  |  |  |  |  |  | 4 years |  |  |  |  |
Maximum aggregate milestone payments to be made |  |  |  |  |  |  | $ 13,000 |  |  |  |  |
Maximum antibodies partially exercised under commercialization option | item |  |  |  |  |  |  | 10 |  |  |  |  |
Percentage of option fee to be paid on partial exercise of commercialization option |  |  |  |  |  |  | 65.00% |  |  |  |  |
Additional payment to be made |  |  |  |  |  |  | $ 0 |  |  |  |  |
GSK Agreement |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Sales milestones |  |  |  |  |  | $ 485,000 |  |  |  |  |  |
Additional clinical milestones eligible to receive |  |  |  |  |  | 60,000 |  |  |  |  |  |
Regulatory milestones eligible to receive |  |  |  |  |  | $ 155,000 |  |  |  |  |  |
Term of agreement |  |  |  |  |  | 10 years |  |  |  |  |  |
GSK Agreement | Surface |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments earned |  |  |  |  | $ 30,000 |  |  |  |  |  |  |
Junshi Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Undisclosed preclinical | item |  | 2 |  |  |  |  |  |  |  |  |  |
Accrued milestone payment |  |  |  |  |  |  |  |  |  |  | $ 25,000 |
Decrease in Research and Development Expenses for Release of Certain Liabilities |  |  |  |  |  |  |  | 4,800 |  |  |  |
Research and development |  |  |  |  |  |  |  | 8,000 |  |  |  |
Royalties due |  |  |  |  |  |  |  | 1,500 |  |  |  |
Junshi Biosciences | Intangible assets, net and accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Accrued milestone payment |  |  |  | $ 25,000 |  |  |  |  |  |  |  |
Junshi Biosciences | Accrued and other current liabilities |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  |  | 12,500 | 25,000 |  |  |
Junshi Biosciences | Accounts payable |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  |  | 400 | $ 6,300 |  |  |
Junshi Biosciences | Licensed Products |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Maximum paid amount for co-development activities (per licensed compound) |  | $ 25,000 |  |  |  |  |  |  |  |  |  |
Junshi Biosciences | Toripalimab (LOQTORZI) |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, upfront amount paid |  | 150,000 |  |  |  |  |  |  |  |  |  |
Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones |  |  |  |  |  |  |  | 380,000 |  |  |  |
Milestone payments paid |  |  |  |  |  |  |  | $ 25,000 |  |  |  |
CHS-006 anti-TIGIT antibody |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
License Agreement Fee |  | $ 35,000 |  |  | 35,000 |  |  |  |  |  |  |
Collaboration agreement, royalty on net sales for each exercised option, percentage |  | 18.00% |  |  |  |  |  |  |  |  |  |
Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program |  | $ 85,000 |  |  |  |  |  |  |  |  |  |
CHS-006 anti-TIGIT antibody | Anti-TIGIT Antibody and IL-2 cytokine |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program |  |  |  |  | $ 170,000 |  |  |  |  |  |  |
LOQTORZI |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of royalties on net sales |  |  |  |  |  |  |  | 20.00% |  |  |  | 20.00%
Canada license agreement |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |  |  |  |  |  |
Company an upfront payment received |  |  |  |  |  |  |  | $ 6,300 |  |  |  |
Regulatory and sales milestones eligible to receive |  |  |  |  |  |  |  | $ 51,500 |  |  |  |
Renewal term |  |  |  |  |  |  |  | 10 years |  |  |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. + References No definition available. + Details
Name: | chrs_AccruedMilestonePayment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Additional milestone payments upon achievement of with subject to FDA approval + References No definition available. + Details
Name: | chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents co-development, regulatory and technology transfer costs. + References No definition available. + Details
Name: | chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of additional clinical milestones eligible to receive + References No definition available. + Details
Name: | chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional payment to be made + References No definition available. + Details
Name: | chrs_CollaborationAgreementAdditionalPaymentToBeMade
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum aggregate milestone payments to be made + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone payments earned + References No definition available. + Details
Name: | chrs_CollaborationAgreementMilestonePaymentsEarned
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of option exercise fee per program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of royalty on net sales for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for payment of nominal research maintenance fee + References No definition available. + Details
Name: | chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of regulatory milestones eligible to receive + References No definition available. + Details
Name: | chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Renewal term of agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementRenewalTerm
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of agreement + References No definition available. + Details
Name: | chrs_CollaborationAgreementTerm
Namespace Prefix: | chrs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents costs associated to a collaboration agreement. + References No definition available. + Details
Name: | chrs_CollaborationCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of regulatory and sales milestones eligible to receive under the collaborative arrangement. + References No definition available. + Details
Name: | chrs_CollaborativeArrangementRegulatoryAndSalesMilestonesEligibleToReceive
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The upfront payment received by the company under the collaborative arrangement. + References No definition available. + Details
Name: | chrs_CollaborativeArrangementUpfrontPaymentReceived
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of decrease in research and development expenses for release of certain liabilities. + References No definition available. + Details
Name: | chrs_DecreaseInResearchAndDevelopmentExpensesForReleaseOfCertainLiabilities
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the maximum paid amount for co-development activities. + References No definition available. + Details
Name: | chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum antibodies partially exercised under commercialization option + References No definition available. + Details
Name: | chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount per each installment of milestone payments under collaborative arrangements. + References No definition available. + Details
Name: | chrs_MilestonePaymentsAmountPerEachInstallment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow associated with milestone based license fee payment. + References No definition available. + Details
Name: | chrs_MilestonePaymentsPaidForLicenseFee
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Minimum antibodies to be commercialized under commercialization option + References No definition available. + Details
Name: | chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption
Namespace Prefix: | chrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition percentage of profit shared. + References No definition available. + Details
Name: | chrs_PercentageOfGrossProfitsOnSales
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of option fee to be paid on partial exercise of commercialization option + References No definition available. + Details
Name: | chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalties incurred on net sales. + References No definition available. + Details
Name: | chrs_PercentageOfRoyaltiesOnNetSales
Namespace Prefix: | chrs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of regulatory milestones eligible to pay. + References No definition available. + Details
Name: | chrs_RegulatoryMilestonesEligibleToPay
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of sales milestones entitled. + References No definition available. + Details
Name: | chrs_SalesMilestonesEntitled
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=chrs_SurfaceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_ToripalimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_Chs006AntiTigitAntibodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_LoqtorziMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_CanadaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |